IntrinsicIntrinsic
← All summaries

VitaNova Life Sciences Corp

YJGJD
Financials & Chart →

Business Summary

VitaNova Life Sciences Corporation operates in the U.S. consumer health, beauty, and lifestyle industry, specifically within the dietary supplement and healthy food products sectors. The company develops, acquires, markets, and sells branded nutritional supplements, functional beverages, and complementary lifestyle products. The dietary supplement industry is large and highly fragmented with few barriers to entry, and the market is highly sensitive to the introduction of new products that may rapidly capture significant market share.

The U.S. nutritional supplements retail industry is highly competitive, with competition based on brand recognition, product quality, price, and innovation. Primary competitors include domestic and international manufacturers, specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies, and e-commerce companies. Certain competitors may have significantly greater financial, technical, and marketing resources, and may be able to adapt to changes in consumer preferences more quickly or generate greater brand recognition. The company believes its brands are strengthened by formulations developed using a science-informed approach and internal review of publicly available research without claiming clinical proof of effectiveness.

The company generates revenue through a Business-to-Business commercial model, working with regional distributors and channel partners to leverage their existing traffic resources and sales infrastructures. Revenue streams include the sale of dietary supplement products, the sale of healthy food products, and consulting service income. The company operates an asset-light model where product strategy, formulation oversight, brand management, and regulatory compliance are conducted internally, while production, packaging, and fulfillment are performed by qualified third-party contract manufacturers and logistics partners. Customer segments include consumers in the United States, Hong Kong, and China, with partners relying on diversified online traffic channels including Douyin Cross-border, Weidian Cross-border, and direct-to-consumer sales in the United States.

The company manages a dual-brand structure consisting of GeneCode and AMZ. GeneCode is positioned as a wellness brand offering formulations developed through an internal review process that considers publicly available nutritional-science literature, ingredient-level research, and supplier technical data, targeting consumers seeking wellness-oriented formulations. AMZ serves as the company's functional-nutrition line, offering practical, accessible dietary-supplement formulations intended to support routine nutritional needs and daily-wellness maintenance, emphasizing broad consumer reach, value accessibility, and lifestyle-oriented product design. During the year ended April 30, 2026, the company started a new product line of sale of healthy food products including olive juice, white sesame oil, and aloe vera drink, generating revenue of $1,062,918 from this segment. The dietary supplement segment generated revenue of $1,947,620 for the year ended April 30, 2026. The consulting service income segment generated $15,000 in revenue for the same period.

The company also maintains a small consulting business that provides general business-advisory and administrative support services to third parties, including basic business-management assistance, operational consulting, and related administrative support. The consulting segment generated $10,838 in revenue for the year ended April 30, 2025.

On January 9, 2026, the company changed its name from Yijia Group Corp. to VitaNova Life Sciences Corporation, and the ticker symbol changed to VNOV. On January 27, 2026, a 1-for-3 reverse stock split of common stock became effective. On November 12, 2025, the company filed a Certificate of Amendment to increase authorized shares of Common Stock to 200,000,000 and to authorize 10,000,000 shares of blank check preferred stock. On November 21, 2025, the company designated 3,000,000 shares of Series A Preferred Stock. On March 6, 2026, the company founded VitaNova Global Foods Corporation as a wholly owned subsidiary incorporated in Nevada for marketing and supplying healthy food products. Share-based compensation of $179,400 was recorded during the year ended April 30, 2026.

For the fiscal year ended April 30, 2026, total revenues were $3,025,538 , compared to $2,662,105 in the prior year, representing an increase of $363,433 or 14% . Gross profit was $910,589 for fiscal 2026 versus $1,575,710 for fiscal 2025, a decrease of $665,121 or 42% . The gross profit margin was 30% in fiscal 2026 compared to 59% in fiscal 2025. The company reported a net loss of $37,304 for fiscal 2026 compared to net income of $850,746 for fiscal 2025. Basic loss per share was $0.004 in fiscal 2026 versus basic earnings per share of $0.10 in fiscal 2025.

Business Outlook

The company's primary growth vector is the expansion of its healthy food products line, which was launched during the year ended April 30, 2026. This new product line, including olive juice, white sesame oil, and aloe vera drink, generated $1,062,918 in revenue shortly after launch. Management views this food trading business primarily as a source of revenue and cash flow to support the company's broader operations. The company formed VitaNova Global Foods Corporation on March 6, 2026, to develop and expand the food trading business, including sourcing, distribution, import and export of healthy food products and related supply chain activities.

The company's second growth vector is its multi-channel sales and marketing strategy, which includes direct-to-consumer channels, livestreaming platforms, retail partners, and wellness service networks. The company leverages social media, KOL and influencer collaborations, and community-driven content to strengthen brand trust and improve customer acquisition efficiency. An upcoming subscription platform is expected to enhance customer retention, increase purchase frequency, and contribute to recurring revenue. The company also works with regional wellness providers and selected retail distributors to expand offline presence, with a focus on scalable expansion in the United States and internationally.

The gross profit margin declined from 59% in fiscal 2025 to 30% in fiscal 2026, primarily attributable to the lower-margin healthy food products line, which had a profit margin of approximately 10% due to marketing and promotional pricing to attract customers. Cost of revenue as a percentage of net revenue was approximately 70% for fiscal 2026 compared to 41% for fiscal 2025. General and administrative expenses increased by $575,673 or 364% , primarily due to increases in legal and professional fees and stock compensation expense.

The company operates an asset-light model relying on third-party contract manufacturers and logistics partners for production, packaging, and fulfillment. The company leases approximately 700 square feet of storage space at 31 Lakeland Ave, Babylon, New York 11702 on a month-to-month basis. As of the date of the filing, the company had a total of 7 full-time employees and intends to grow its employee base in response to the demands and requirements of the business. The company does not maintain product liability insurance, clinical trial insurance, key person insurance, business interruption insurance, or other material commercial insurance coverage.

The company has not declared any cash dividends on its common stock since inception and does not anticipate paying any dividends in the foreseeable future. The present policy is to apply cash to investments in product development, acquisitions, or expansion. Share-based compensation of $179,400 was recorded during fiscal 2026. The company did not repurchase any equity securities during the fiscal year ended April 30, 2026. No specific R&D spending levels or capital expenditure plans are disclosed in the filing.

The company faces a structural headwind from its limited operating history and start-up stage of operations, having generated limited revenues since inception. The company cannot guarantee success in its business operations and is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products. The company's customer concentration risk is significant, with three customers accounting for 54% of total net revenues for the year ended April 30, 2026, and three customers accounting for 91% of total net revenues for the year ended April 30, 2025.

The company faces geographic and regulatory constraints. For the year ended April 30, 2026, revenue from the United States was $2,679,960 , from Hong Kong was $345,578 , and from China was $0 . The company's products sold in foreign countries are subject to regulation under various national, local, and international laws that may categorize products as medicines or food supplements based on regionally-specific regulations. Government regulations in foreign countries may prevent or delay the introduction or require the reformulation of certain products.

Risk Factors

The company faces significant customer concentration risk, as three customers accounted for 54% of total net revenues for fiscal 2026 and three customers accounted for 91% of total net revenues for fiscal 2025. The company also faces vendor concentration risk, with four vendors accounting for 100% of purchases for fiscal 2026 and one vendor accounting for 86% of purchases for fiscal 2025. The company does not maintain product liability insurance, clinical trial insurance, key person insurance, business interruption insurance, or other material commercial insurance coverage, exposing it to uninsured losses. The company is in a start-up stage of operations with limited revenues since inception and has limited capital resources, with total current assets of $2,430,523 and total current liabilities of $395,781 as of April 30, 2026. The company relies extensively on information technology systems and third-party service providers for its direct-to-consumer sales model, and as a smaller reporting company with limited financial and personnel resources dedicated to information security, it is vulnerable to cybersecurity threats.

Management Priorities

Management's message emphasizes the company's transformation into a U.S.-focused consumer health, beauty, and lifestyle company with a dual-brand structure and the launch of a new healthy food products line.The strategic priorities emphasized for the period ahead include expanding the healthy food products business through VitaNova Global Foods Corporation, continuing the multi-channel sales and marketing strategy including the upcoming subscription platform, and maintaining an asset-light operating model with third-party manufacturing and logistics partners.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  2. [2] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  3. [3] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  4. [4] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  5. [5] Item 1, Business — November 2025 Change of Share Capital
  6. [6] Item 1, Business — November 2025 Change of Share Capital
  7. [7] Item 1, Business — November 2025 Series A Preferred Stock
  8. [8] Item 8, Consolidated Statements of Changes in Shareholders' Equity
  9. [9] Item 7, MD&A — Results of Operations; Item 8, Consolidated Statements of Operations
  10. [10] Item 7, MD&A — Results of Operations; Item 8, Consolidated Statements of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Results of Operations; Item 8, Consolidated Statements of Operations
  14. [14] Item 7, MD&A — Results of Operations; Item 8, Consolidated Statements of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations; Item 8, Consolidated Statements of Operations
  20. [20] Item 7, MD&A — Results of Operations; Item 8, Consolidated Statements of Operations
  21. [21] Item 8, Consolidated Statements of Operations
  22. [22] Item 8, Consolidated Statements of Operations
  23. [23] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 2, Properties
  32. [32] Item 1, Business — Human Capital Resources
  33. [33] Item 8, Consolidated Statements of Changes in Shareholders' Equity
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  37. [37] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  38. [38] Item 7, MD&A — Results of Operations; Note 3 — Segment Reporting
  39. [39] Item 7, MD&A — Results of Operations
  40. [40] Item 7, MD&A — Results of Operations
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 7, MD&A — Results of Operations
  43. [43] Item 8, Consolidated Balance Sheets
  44. [44] Item 8, Consolidated Balance Sheets
  45. [45] Item 8, Consolidated Statements of Operations
  46. [46] Item 8, Consolidated Statements of Operations
  47. [47] Item 8, Consolidated Statements of Operations
  48. [48] Item 8, Consolidated Statements of Operations
  49. [49] Item 8, Consolidated Statements of Operations
  50. [50] Item 8, Consolidated Statements of Operations
  51. [51] Item 8, Consolidated Statements of Operations
  52. [52] Item 8, Consolidated Statements of Operations
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 7, MD&A — Results of Operations
  55. [55] Item 8, Consolidated Statements of Operations
  56. [56] Item 8, Consolidated Statements of Operations
  57. [57] Item 8, Consolidated Statements of Cash Flows
  58. [58] Item 8, Consolidated Statements of Cash Flows
  59. [59] Item 8, Consolidated Balance Sheets
  60. [60] Item 8, Consolidated Balance Sheets
  61. [61] Item 8, Consolidated Balance Sheets
  62. [62] Item 8, Consolidated Balance Sheets
  63. [63] Item 8, Consolidated Statements of Cash Flows; Note 4 — Accounts Receivable Net
  64. [64] Item 8, Consolidated Statements of Changes in Shareholders' Equity
  65. [65] Note 3 — Segment Reporting
  66. [66] Note 3 — Segment Reporting
  67. [67] Note 3 — Segment Reporting
  68. [68] Note 3 — Segment Reporting

Analysis on 7/29/2026